Abstract
We have evaluated the effectiveness of combining the different characteristics of retrovirus and adenovirus to apply the herpes simplex virus thymidine kinase gene (HSVtk) and ganciclovir (GCV) treatment for gene therapy of pancreatic cancer. Transduction of NP-18 human pancreatic cells in culture by either the adenoviral vector (ADV/tk) or the retroviral vector (Rv/tk) followed by GCV treatment resulted in a GCV dose-dependent cytotoxic effect. A bystander effect was determined, both in NP-18 cultures and in xenogeneic cell mixtures of NP-18 and PA317 cells. Studies in vivo indicated that the effectiveness of tumor regression after HSVtk gene transfer and GCV treatment was dependent first on the tumor size at the time of viral injection and secondly, in large tumors, on the type of virus administered. The administration of the viral combination (ADV/tk + vector producer cells VPC-Rv/tk) was the best approach tested and resulted in a dramatic reduction in tumor mass after 4 days of GCV treatment which was maintained for the treatment period. Remarkably, two animals presented a complete eradication of the tumor. Thus, the HSVtk/GCV system when administered using a viral combination (ADV/tk + VPC-Rv/tk), may be a promising suicide gene therapy for pancreatic carcinomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout







References
Warshaw AL, Fernandez-del Castillo C . Pancreatic carcinoma New Engl J Med 1992 326: 455–465
Beger HG, Link KH, Poch B, Gansauge F . Pancreatic cancer recent progress in diagnosis and treatment In: Neoptolemos JP, Lemoine NR (eds) . Pancreatic Cancer. Molecular and Clinical Advances Blackwell: Oxford 1996 pp 227–235
Rigg A, Sikora K . Genetic prodrug activation therapy Mol Med Today 1997 3: 359–366
Cheng YC et al. Unique spectrum of activity of 9-{(1,3-dihydroxy-2-propoxy)methyl}-guanine against herpes viruses in vitro and its mode of action against herpes symplex virus type 1 Proc Natl Acad Sci USA 1983 80: 2167–2770
Caruso M . Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase Mol Med Today 1996 2: 212–217
Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors Science 1992 256: 1550–1552
Gagandeep S et al. Prodrug-activated gene therapy: involvement of an immunological component in the ‘bystander effect’ Cancer Gene Ther 1996 3: 83–88
Colombo BM et al. The bystander effect: association of U-87 cell death with ganciclovir-mediated apoptosis of nearby cells and lack of effect in athymic mice Hum Gene Ther 1995 6: 763–772
Elshami AA et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro Gene Therapy 1996 3: 85–92
Vrionis FD et al. The bystander effect exerted by tumor cells expressing the herpes simplex virus thymidine kinase (HSVtk) gene is dependent on connexin expression and cell communication via gap junctions Gene Therapy 1997 4: 577–585
Ram Z et al. In situ retrovirus-mediated gene transfer for the treatment of brain tumors in rats Cancer Res 1993 53: 83–88
Eastham JA et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by Ganciclovir in mouse and human prostate cancer models Hum Gene Ther 1996 7: 515–523
Haffe HA et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver Nat Genet 1992 1: 372–378
Takamiya Y et al. An experimental model of retrovirus gene therapy for malignant brain tumors J Neurosurg 1993 79: 104–110
Feng M et al. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector Nat Biotechnol 1997 15: 866–870
Garcia C et al. Characterization of new human pancreatic cancer cell lines expressing p21 and Gadd45 by p53-independent pathways Cancer Res 1998 (submitted)
Ishii-morita H et al. Mechanism of bystander effect killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment Gene Therapy 1997 4: 244–251
DiMaio JM et al. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo Surgery 1994 116: 205–213
Rosenfeld ME et al. Pancreatic carcinoma cell killing via adenoviral mediated delivery of herpes simplex virus thymidine kinase gene Ann Surg 1997 225: 609–620
Smiley WR et al. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSVtk retroviral vector in established solid tumors Hum Gene Ther 1997 8: 965–977
Kuriyama S et al. Tissue-specific expression of HSVtk gene can induce efficient antitumor effect and protective immunity to wild-type hepatocellular carcinoma Int J Cancer 1997 71: 470–475
Link CJ, Moorman D . A phase I trial of in vivo gene therapy with the herpes simplex thymidine kinase/ganciclovir system for the treatment of refractory or recurrent ovarian cancer Hum Gene Ther 1996 7: 1161–1179
Becker TC et al. Use of recombinant adenovirus for metabolic engineering of mammalian cells Meth Cell Biol 1994 43: 161–189
Izquierdo M et al. Long-term rat survival after malignant brain tumor regression by retroviral gene therapy Gene Therapy 1995 2: 66–69
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carrió, M., Romagosa, A., Mercadé, E. et al. Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. Gene Ther 6, 547–553 (1999). https://doi.org/10.1038/sj.gt.3300846
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3300846
Keywords
- pancreatic tumors
- HSVtk
- adenovirus
- retrovirus
- bystander effect
This article is cited by
-
Optimizing oncolytic virotherapy in cancer treatment
Nature Reviews Drug Discovery (2019)
-
E-cadherin contributes to the bystander effect of TK/GCV suicide therapy and enhances its antitumoral activity in pancreatic cancer models
Gene Therapy (2011)
-
GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the TAT8-TK as a late gene in a pancreatic tumour model
Gene Therapy (2007)
-
Molecular Targeting of Pancreatic Disorders
World Journal of Surgery (2005)
-
Targeting of suicide gene delivery in pancreatic cancer cells via FGF receptors
Cancer Gene Therapy (2002)